Portfolio company Dark Blue Therapeutics was acquired in a deal worth up to $840m.
Dark Blue Therapeutics is an innovative drug discovery biotechnology company based in Oxford, UK, pioneering the next generation of precision medicines to deliver a portfolio of transformative cancer therapies
Dark Blue Therapeutics is an innovative drug discovery biotechnology company based in Oxford, UK, pioneering the next generation of precision medicines to deliver a portfolio of transformative cancer therapies. The company leverages groundbreaking cancer biology insights from Oxford University to discover and develop innovative precision medicines that exploit novel vulnerabilities and dependencies.